저자의 연구 키워드

저자의 연구 키워드

#갑상선기능저하증

#갑상선암

#골격근

#두경부 종양

#발생률

#베타 소단위

#비소세포폐암.

#사람융모성성선자극호르몬

#상피세포성장인자수용체

#소세포암

#약제유발

#유두갑상선암종

#육종

#전이

#폐암

#표적치료제

#혀 종양

#Abscopal effect

#Acute kidney injury

#ADC

#Adenocarcinoma

#Adenoid cystic carcinoma

#Adjuvant

#Adjuvant chemotherapy

#Administration

#Age groups

#Alectinib

#Anaplastic lymphoma kinase

#Anthracycline

#Aromatase inhibitors

#beta Subunit

#Bevacizumab

#Blood platelets

#BRAF

#BRAFV600E

#Brain

#Brain metastasis

#Breast neoplasms

#Brigatinib

#cancer patients

#Carcinoma

#Central nervous system

#Chemoradiotherapy

#Chemotherapy

#Chorionic gonadotropin

#Cisplatin

#Clinical Trial

#Comorbidity

#Dabrafenib

#Desmoplastic small round cell tumor

#Diffuse large B-cell lymphoma

#Diffusion-weighted imaging

#Disease-free survival

#Docetaxel

#Doxorubicin

#Drug-related side effects and adverse reactions

#Durvalumab

#EGFR genes

#EGFR mutant NSCLC

#EGFR mutation

#Elderly

#epidermal growth factor

#Epidermal growth factor receptor

#Epidermal growth factor receptor tyrosine kinase inhibitor

#ErbB receptors

#Erlotinib

#Esophageal carcinoma

#Exemestane

#Fluorescence in situ hybridization

#Gefitinib

#Gemcitabine

#Glioblastoma

#Glioma

#Head and neck neoplasms

#Health care costs

#High-grade glioma

#Hospices

#Human

#Human papillomavirus

#Hypoglycemia

#Hypothyroidism

#Immune checkpoint inhibitor

#Immune therapy

#Immunohistochemistry

#Immunotherapy

#Incidence

#Induction chemotherapy

#Insulinoma

#Intensity-modulated radiotherapy

#Interleukin-1beta

#Interstitial lung diseases

#Junction sequence of the fusion gene

#Ki-67

#Kidney

#Lazertinib

#Leptomeningeal Metastases

#Leptomeningeal metastasis

#Leukocytes

#Lung injury

#Lung neoplasms

#Lymphoma

#Manual

#Metachronous

#Metastasis

#Methotrexate

#MGMT

#Multiple myeloma

#Muscle

#Nasal cavity

#Neoplasm metastasis

#Nepolasm metastasis

#Nomograms

#Non-small cell lung cancer

#Non-small cell lung carcinoma

#Non–small cell lung carcinoma

#non-small-cell lung

#Non–small-cell lung cancer

#Non-small-cell lung carcinoma

#Non–small-cell lung carcinoma

#NUT carcinoma

#NUTM1 fusion gene

#Nutrition status

#Oligorecurrence

#OPB-31121

#Oral

#Orbit evisceration

#Oropharyngeal neoplasms

#Osimertinib

#Paclitaxel

#Pancreatic neuroendocrine tumor

#Papillary thyroid carcinoma

#Paranasal sinuses

#Pembrolizumab

#Pemetrexed

#Perfusion imaging Susceptibility-weighted imaging

#P-glycoprotein

#Pharmacokinetics

#Phase 1

#Phase I

#PIK3CA

#Platinum

#polypharmacy

#potential drug interaction

#Pralsetinib

#Prognosis

#Prognostic factor

#Programmed death ligand 1

#Protein kinase inhibitors

#Proteinuria

#Proton therapy

#Radiation therapy-related change

#Radical radiotherapy

#Radiotherapy

#Receptor

#RET

#RET-rearrangement

#Reverse transcriptase polymerase chain reaction

#Salivary gland neoplasms

#Second neoplasm

#Segmentation

#Semiautomatic

#Skeletal

#Small cell carcinoma

#Small cell lung carcinoma

#Solid Tumor

#Spindle cell carcinoma

#Squamous cell carcinoma of head and neck

#STAT3

#STAT3 inhibitor

#Sunitinib

#Survival

#Synchronous neoplasm

#Systemic chemotherapy

#Targeted molecular therapy

#Taxane

#Temozolomide

#Terminal care

#Third-generation EGFR tyrosine kinase inhibitor

#Thromboembolism

#Thyroid cancer

#Thyroid neoplasms

#Tongue neoplasms

#Tonsil neoplasms

#Toxicity

#Trametinib

#Transforming growth factor beta1

#Tremelimumab

#Trend

#Tumor recurrence

#Tyrosine kinase inhibitor

#Tyrosine-kinase inhibitor

#Vascular endothelial growth factor

#Vinorelbine